{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:07Z","timestamp":1783617367412,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>A comprehensive assessment of kidney cancer (KC) that incorporated spatiotemporal, demographic, and socioeconomic dimensions was lacking. This study aimed to establish a comprehensive global assessment framework for KC burden spanning 1990 to 2021. Epidemiologic data on KC were sourced from the Global Burden of Disease 2021 study, generating KC incidence, prevalence, and disability-adjusted life-year (DALY) estimates. In 2021, there were 1,961,210.85 (95% uncertainty interval [UI]: 1,861,776.54\u20132,051,838.01) prevalent cases of KC, 387,828.72 (95% UI: 365,359.71\u2013406,635.25) new KC cases, and 4,016,362.12 (95% UI: 3,806,832.21\u20134,246,783.03) KC DALYs. the high-socio-demographic index (SDI) group had the highest case age-standardized rates (ASRs) and number of the 3 indicators, middle-SDI regions showed the sharpest increase in incidence and prevalence ASRs, while the ASR of DALYs for low-middle-SDI regions demonstrated the most significant increase. The slope index of inequality recorded a near tripling (5\u201312) in incidence inequality between top- and bottom-ranking SDI countries spanning 1990 through 2021. Other indicators followed a similar profile. The numbers of the 3 indicators for KC are projected to increase globally between 2022 and 2040, while the corresponding ASRs will decrease annually. The global burden of KC has remained high for 32 years. High-SDI regions have borne a substantial disease burden, predominantly driven by aging populations, whereas low-middle- and middle-SDI regions have exhibited steeper increasing burden trends, representing critical targets for future prevention efforts. Projected increases in KC burden demand proactive scaling of healthcare resources, declining ASRs warrant vigilance against unequal burden distribution, effective strategies must prevent overall improvement from masking localized deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049500","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:00:17Z","timestamp":1783098017000},"page":"e49500","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Trends and health inequalities in the global burden of kidney cancer from 1990 to 2021, with projections to 2040"],"prefix":"10.1097","volume":"105","author":[{"given":"Dingtian","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5408-9397","authenticated-orcid":false,"given":"Chunyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide.","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"R2-20260709","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-18-1354","article-title":"The metabolic basis of kidney cancer.","volume":"9","author":"Linehan","year":"2019","journal-title":"Cancer Discov"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfae036","article-title":"Global epidemiology of kidney cancer.","volume":"39","author":"Cirillo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"13710","DOI":"10.1038\/s41598-024-64521-7","article-title":"Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990\u20132019).","volume":"14","author":"Safiri","year":"2024","journal-title":"Sci Rep"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"1358017","DOI":"10.3389\/fnut.2024.1358017","article-title":"What was the global burden of kidney cancer attributable to high body mass index from 1990 to 2019? There existed some points noteworthy.","volume":"11","author":"Yao","year":"2024","journal-title":"Front Nutr"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"117252","DOI":"10.1016\/j.ecoenv.2024.117252","article-title":"Global trends and projections of occupational trichloroethylene (TCE) exposure-associated kidney cancer: Insights of the Global Burden of Disease (GBD) Study 2021 from 1990 to 2021 and prediction to 2050.","volume":"287","author":"Huang","year":"2024","journal-title":"Ecotoxicol Environ Saf"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates.","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"994619","DOI":"10.3389\/fpubh.2022.994619","article-title":"Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019.","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40249-022-01009-4","article-title":"Age-period-cohort analysis of pulmonary tuberculosis reported incidence, China, 2006\u20132020.","volume":"11","author":"Dong","year":"2022","journal-title":"Infect Dis Poverty"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3390\/ijerph19126969","article-title":"Correction: Schlotheuber, A.; Hosseinpoor, A.R. Summary measures of health inequality: a review of existing measures and their application. Int. J. Environ. Res. Public Health 2022, 19, 3697.","volume":"19","author":"Schlotheuber","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"e1388","DOI":"10.1016\/S2214-109X(19)30360-2","article-title":"Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990\u20132017: a population-based study.","volume":"7","author":"Ordunez","year":"2019","journal-title":"Lancet Glob Health"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.puhe.2022.04.015","article-title":"Global disease burden of COPD from 1990 to 2019 and prediction of future disease burden trend in China.","volume":"208","author":"Hu","year":"2022","journal-title":"Public Health"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention.","volume":"70","author":"Liu","year":"2019","journal-title":"J Hepatol"},{"key":"R18-20260709","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/sim.3733","article-title":"Estimating average annual per cent change in trend analysis.","volume":"28","author":"Clegg","year":"2009","journal-title":"Stat Med"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1038\/s41598-024-61300-2","article-title":"Decomposing difference in the kidney cancer burden measures between 1990 and 2019 based on the global burden of disease study.","volume":"14","author":"Ayubi","year":"2024","journal-title":"Sci Rep"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/0008-5472.CAN-13-2681","article-title":"ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2\u03b1\/VEGF signaling pathway.","volume":"74","author":"He","year":"2014","journal-title":"Cancer Res"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"e22163","DOI":"10.1096\/fj.202101645R","article-title":"Estrogen receptor beta increases clear cell renal cell carcinoma stem cell phenotype via altering the circPHACTR4\/miR-34b-5p\/c-Myc signaling.","volume":"36","author":"Wang","year":"2022","journal-title":"FASEB J"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/1878-0261.12377","article-title":"Targeting newly identified ER\u03b2\/TGF-\u03b21\/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ER\u03b2 selective antagonist in renal cell carcinoma.","volume":"12","author":"Song","year":"2018","journal-title":"Mol Oncol"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/CLEP.S400646","article-title":"Epidemiological trends of kidney cancer along with attributable risk factors in China from 1990 to 2019 and its projections until 2030: an analysis of the global burden of disease study 2019.","volume":"15","author":"Xu","year":"2023","journal-title":"Clin Epidemiol"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.3390\/ijms23063404","article-title":"Renal cell cancer and obesity.","volume":"23","author":"Gluba-Brz\u00f3zka","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults.","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"1119374","DOI":"10.3389\/fpubh.2023.1119374","article-title":"Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: systematic analysis for the Global Burden of Disease Study 2019.","volume":"11","author":"Tian","year":"2023","journal-title":"Front Public Health"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.eururo.2010.10.029","article-title":"Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis.","volume":"59","author":"Sun","year":"2011","journal-title":"Eur Urol"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality.","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"R29-20260709","doi-asserted-by":"crossref","first-page":"13862","DOI":"10.1038\/s41598-020-70840-2","article-title":"The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017.","volume":"10","author":"Safiri","year":"2020","journal-title":"Sci Rep"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-020-00195-3","article-title":"Trends and projections of kidney cancer incidence at the global and national levels, 1990\u20132030: a Bayesian age-period-cohort modeling study.","volume":"8","author":"Du","year":"2020","journal-title":"Biomark Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:00:54Z","timestamp":1783616454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":30,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049500","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2025-08-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}